Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma

Published:2024-09 Issue: Volume: Page:1-6
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Wang Siying¹,Xie Ouyang²³,Wu Meiyu²³,Xiang Heng²³,Tan Chongqing²³,Wan Xiaomin²³^ORCID

Affiliation:

1. Department of Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, Hunan, China

2. Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

3. Institute of Clinical Pharmacy, Central South University, Changsha, Hunan, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2399246

Reference21 articles.

1. National Institutes of Health. National Cancer Institute; surveillance epidemiology and end results program. Cancer stat facts: kidney and renal pelvis cancer. 2023 [cited 2023 Jan 14]. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html

2. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

3. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

4. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

5. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial